摘要
目的观察诺雷德联合他莫昔芬治疗对年轻乳腺癌患者生活质量和性生活满意度的影响。方法选取激素受体阳性且接受诺雷德联合他莫昔芬内分泌治疗的年轻乳腺癌患者42例(实验组),同时筛选同期仅使用他莫昔芬内分泌治疗的年轻乳腺癌患者42例(对照组)作对照。使用乳腺癌治疗功能评估(FACT-B)和经修改的女性性功能简要指数(BISF-W)问卷调查表对两组患者进行问卷调查,评估两组患者的生活质量和性生活满意度。结果两组生理状况、社会/家庭情况、情感状况、功能状况、附加关注的得分,以及性生活满意度的比较差异均无统计学意义(P>0.05)。结论对于激素受体阳性的年轻乳腺癌患者,诺雷德联合他莫昔芬治疗不会降低其生活质量和性生活满意度。
Objective To observe the effect of zoladex combined with tamoxifen on the quality of life(QOL)and sexual satisfaction in young breast cancer patients.Methods A total of 42 young patients with breast cancer with hormone-receptor positive who received the treatment with zoladex combined with tamoxifen were selected as the Experimental Group while 42 young patients with breast cancer who only received the treatment with tamoxifen at the same period were selected as the Control Group.The Functional Assessment of Cancer Therapy-Breast(FACT-B 4 th Edition)and a modified Brief Index of Sexual Function for Women(BISF-W)questionnaire were used to study the quality of life(QOL)and sexual satisfaction of the two groups.Results There was no statistical difference in the physical status,social and family status,emotional status,functional status,and extra attention as well as the sexual satisfaction between the two groups(P>0.05).Conclusion The combination of zoladex and tamoxifen does not reduce the QOL and sexual life of young breast cancer patients with hormonereceptor positive.
作者
崔世恩
凌飞海
黄志华
马士辉
CUI Shi-en;LING Fei-hai;HUANG Zhi-hua;MA Shi-hui(Department of Breast Surgery,Zhongshan Peopled Hospital,Zhongshan 528400,China)
出处
《广东医科大学学报》
2020年第4期436-439,共4页
Journal of Guangdong Medical University